Elegen, a pioneer in DNA manufacturing, has entered into a collaboration and licensing agreement with GSK (GlaxoSmithKline) to leverage Elegen's proprietary cell-free DNA manufacturing technology in the development of GSK's vaccines and medicines. Elegen will be speaking at the SynBioBeta 2024 conference this May 6-9 at the San Jose Convention Center in California. The agreement includes upfront fees and purchase commitments of Elegen's ENFINIA DNA to support GSK's ongoing work in developing medicines and vaccines, including those based on RNA technology. Additionally, Elegen stands to receive near-term milestone payments related to the development of new product features and the possibility of an equity investment by GSK.

ENFINIA DNA, commercially launched in March of 2023, offers Next-Generation Sequencing (NGS)-verified, high-complexity, clonal-quality, linear DNA with lengths of up to 7kb, delivered in as little as seven business days. What sets Elegen's DNA apart is that it is produced entirely cell-free, offering potential advantages in seamlessly transitioning from discovery to clinical scale-up under Good Manufacturing Practice (GMP). This innovative technology could significantly save time and resources traditionally spent on iterative processes such as cloning, linearizing, and purifying plasmid DNA, as well as generating master cell banks. Elegen's advancements in cell-free DNA manufacturing have the potential to drive the next generation of mRNA, cell, and gene therapies.

The collaboration builds on Elegen's Early Access Program launched in May of 2023, providing select customers with longer and more complex DNA. “Over the past year dozens of customers, including multiple top 10 biopharma, have validated the unprecedented speed, length, accuracy and complexity of our cell-free DNA manufacturing technology,” said Matthew Hill, Ph.D., Elegen founder and CEO. “GSK recognizes the importance of a reliable, turnkey supply of DNA for a variety of applications for which speed, accuracy and quality of DNA synthesis are essential. This collaboration will expand our offering to include the clinical production of genetic medicines potentially including mRNA, cell and viral gene therapies.”

‍